Storm G, van Etten E
Dept. of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, The Netherlands.
Eur J Clin Microbiol Infect Dis. 1997 Jan;16(1):64-73. doi: 10.1007/BF01575123.
To improve the clinical utility of amphotericin B (AmpB), several lipid-based formulations have been developed. The biopharmaceutical aspects related to the parenteral use of colloidal lipid particles as carriers of AmpB are reviewed here. The first part of the review provides an introduction to the parenteral use of colloidal particles for chemotherapy by addressing the concept of a particulate drug carrier system, the pharmaceutical technological issues, and the biological factors governing the potential and limitations of lipid particles for effective drug delivery. The second part is devoted to AmpB lipid formulations. The pharmaceutical characteristics of the various industrially produced formulations, their pharmacokinetics and possible mechanisms of action, and potential future developments are described.
为提高两性霉素B（AmpB）的临床应用价值，已开发出几种基于脂质的制剂。本文综述了与将胶体脂质颗粒作为AmpB载体进行肠胃外给药相关的生物制药方面。综述的第一部分通过阐述颗粒药物载体系统的概念、制药技术问题以及决定脂质颗粒有效药物递送潜力和局限性的生物学因素，介绍了胶体颗粒在化疗肠胃外给药中的应用。第二部分专门讨论AmpB脂质制剂。描述了各种工业生产制剂的药学特性、它们的药代动力学和可能的作用机制以及潜在的未来发展。
